Prelude Therapeutics Incorporated
Price Action
Technical Summary
STAGE 2 UPTRENDPrelude Therapeutics Incorporated is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings growth of 69% provides fundamental context to the price action. Investors should exercise caution due to high volatility (131% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.09 | +6.97% | ABOVE |
| 50 SMA | $4.35 | +0.64% | ABOVE |
| 100 SMA | $3.73 | +17.39% | ABOVE |
| 150 SMA | $3.16 | +38.61% | ABOVE |
| 200 SMA | $2.73 | +60.70% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PRLD in an uptrend right now?
PRLD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PRLD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PRLD overbought or oversold?
PRLD's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is PRLD outperforming the market?
PRLD has a Relative Strength (RS) Rating of 95 out of 99. Yes, PRLD is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is PRLD in its 52-week range?
PRLD is trading at $4.38, which is 79% of its 52-week high ($5.54) and 76% above its 52-week low ($0.75).
How volatile is PRLD?
PRLD has a Beta of 1.93 and 52-week volatility of 131%. It's more volatile than the S&P 500 - expect bigger swings.